News

NephroSant Announces $16 Million Series A, Led by DaVita Venture Group

NephroSant, a kidney health spin out of UC San Francisco, today announced it has closed its oversubscribed Series A funding round of $16 million.  MORE

Alessa Therapeutics Announces First Australian Patient Enrolled in Biolen-PC Study for New Prostate Cancer Therapy

Founded in 2018 and based on technology developed at the University of California San Francisco, Alessa Therapeutics is developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease. And have announced the enrollment of the first patient in the...

UCSF Technology Sings at San Francisco Opera

In a strange marriage of arts and science, The San Francisco Opera costume department teamed up with doctors from UCSF to create a mask that will allow the company's singers to safely rehearse together -- while greatly diminishing the chances of spreading COVID-19. Video

Sana Announces Closing of Initial Public Offering

Sana Biotechnology, a UCSF startup company focused on creating and delivering engineered cells as medicines, today announced the closing of its upsized initial public offering. The aggregate gross proceeds from the offering were approximately $675.6 million. All of the shares of common stock were...

Weill Neurohub Joins Forces with Genentech and Roche to Advance Neuroscience Research

UC San Francisco and UC Berkeley today announced a long-term research partnership with Genentech, a member of the Roche Group, and its parent company, Roche Holding AG, to speed the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS),...

‘AutoImmunoprofiler’ Builds on Success in Cancer Research to Advance Treatments for Autoimmune Diseases

UCSF Partners With Eli Lilly to Better Understand Underlying Drivers of Autoimmunity and Accelerate the Development of Better Therapies.  MORE

Calico and AbbVie Take UCSF Technology Into Clinical Trials

Calico Life Sciences and AbbVie announced clinical-stage programs in two areas – immuno-oncology and neurodegeneration, currently in Phase I studies. The lead Calico neurodegeneration molecule is based on novel technology licensed from the lab of Peter Walter, Professor of Biochemistry and...

Sana Biotechnology Files for IPO

UCSF start up Sana Biotechnology Inc. intends to go public this year, according to a Wednesday filing with the U.S. Securities and Exchange Commission. The preclinical biotech is looking to raise up to $150 million on the Nasdaq under the symbol SANA. MORE

'Invisible' stem cells evade natural killer cells using immune 'off-switch'

UC San Francisco scientists have discovered a new way to control the immune system's "natural killer" (NK) cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection. The findings could also be used to enhance the ability of cancer...

Alliance Management an Integral Part of Successful Industry Engagement

Convincing a potential industry partner that an initial collaboration is attractive is one thing; keeping that partner on board and strengthening that relationship as the years go on is quite another, and that’s where alliance management comes in. Peter Kotsonis, UCSF's Strategic Alliances...